/PRNewswire/ Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat.
Fox News Flash top headlines are here. Check out what s clicking on Foxnews.com.
Scientists are making dramatic strides toward a goal that once seemed almost unimaginable: Restoring limited vision to people affected by a previously irreversible form of blindness caused by an inherited eye disease called retinitis pigmentosa.
In a paper published Monday in the journal Nature Medicine, researchers working with the Paris-based company GenSight Biologics SA reported that a 58-year-old man who was diagnosed with retinitis pigmentosa 40 years ago was able to locate objects placed on a table after receiving an experimental therapy. And New York City-based company Bionic Sight LLC announced in March that four blind people in an early-stage clinical trial are now able to detect light and motion after undergoing a similar treatment. Those results haven’t yet been published.